Humira has been the world’s best selling medicine since it arrived on the market in 2002. Now, it is finally getting ...

AbbVie lifted its full-year adjusted EPS profit forecast to a range of $12.09 to $12.29 from the prior $11.99 to $12.19. The ...

A technological revolution is helping Scripps Research scientists see the molecules that undermine human health, from ...

Passive income is essential in retirement, but building a dependable stream isn't easy. Fortunately, top-tier dividend stocks ...

(Spencer Platt | Getty Images) President Trump signed an executive action Tuesday ... like blockbuster rheumatoid arthritis ...

AbbVie’s Humira (adalimumab) maintained exclusivity for two decades despite the main patent expiring in 2016. AbbVie secured ...

Rova-T was supposed to be the cancer drug that would bolster AbbVie’s revenues as revenues from the $20bn a year Humira (adalimumab ... perhaps with the usual pictures of shrinking tumours ...

Humira is a type of immunosuppressant known as a tumor necrosis factor (TNF) inhibitor. It’s prescribed to treat autoimmune conditions. TNF is a protein that plays a key role in inflammation. In ...

The prescribed dosage for Humira (adalimumab) may vary depending on a person’s individual treatment plan. Other factors, including specific diagnosis, body weight, and medical history ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...